Ready to activate the moment an outbreak began
In New Delhi this April, health officials from ten South-East Asian nations gathered not to respond to a crisis, but to prepare for one not yet arrived. Working alongside the WHO and the Coalition for Epidemic Preparedness Innovations, they drafted a six-pillar framework designed to transform the region's pandemic research posture from reactive scramble to ready activation. The lesson of COVID-19 — that science cannot be built from scratch in the middle of a storm — has found, at last, a structural answer.
- COVID-19 exposed a painful truth: when a pandemic strikes, research systems that should guide response are still being assembled from nothing.
- Over ninety officials, scientists, and regulators from all ten WHO South-East Asia member states converged in New Delhi to confront this gap head-on.
- A six-pillar framework now proposes to pre-position everything — approved protocols, clinical trial networks, genomic surveillance, fast-release financing — so the next outbreak meets a system already running.
- The region's diversity in capacity is treated not as a weakness but as a design constraint: countries build on existing strengths and draw on regional platforms for what they lack.
- The framework's ultimate test will be political will — whether sustained investment and cross-border partnership can hold together long enough to meet targets like developing a vaccine within 100 days of a new pathogen's identification.
In mid-April, health officials from across South-East Asia gathered in New Delhi for a three-day working session co-chaired by Dr Rakesh Agrawal and Dr Asela Gunawardena of Sri Lanka. Organized by WHO's South-East Asia Regional Office in partnership with the Coalition for Epidemic Preparedness Innovations, the meeting brought together over ninety participants — government representatives, academics, regulators, and vaccine manufacturers — to address a vulnerability COVID-19 had made impossible to ignore: when disease strikes, research systems scramble.
The centerpiece of the meeting was a draft framework built on six pillars: basic science, clinical and epidemiological research, governance and regulatory structures, manufacturing capacity, implementation research, and behavioral science. Beneath these pillars sit five enabling systems — cross-border data sharing, digital infrastructure, rapid financing, pre-established partnerships, and knowledge exchange channels. Together, they are designed to create what officials described as a "ready-to-activate research ecosystem."
The architects of the framework were careful to acknowledge that South-East Asia is not uniform. Countries differ enormously in research capacity and regulatory sophistication, so rather than demanding identical preparedness across all pillars in all nations, the model allows each country to build from its existing strengths while accessing regional platforms for what it lacks — an approach smaller nations found particularly valuable.
The deeper shift the participants endorsed was conceptual: away from reactive research that begins when a crisis arrives, and toward proactive systems already in motion — pre-approved protocols on the shelf, clinical networks already trained, surveillance already running, financing that unlocks in days. As the session closed, the consensus was clear: the framework succeeds only through sustained investment, durable partnerships, and a willingness to act as a region. WHO framed this not as obligation but as opportunity — a chance for South-East Asia to lead globally, and to build research infrastructure that serves both pandemic response and everyday immunization work.
In mid-April, health officials from across South-East Asia gathered in New Delhi for a three-day working session that would reshape how the region prepares for the next pandemic. Over ninety participants—representing all ten member states of the WHO South-East Asia region, along with academics, regulators, vaccine makers, and international partners—convened at the Shangri-La Eros Hotel to tackle a problem that became painfully clear during COVID-19: when disease strikes, research systems scramble. This time, they decided, would be different.
The meeting, held April 14-16 and co-chaired by Dr Rakesh Agrawal and Dr Asela Gunawardena of Sri Lanka, was organized by the WHO's South-East Asia Regional Office in partnership with the Coalition for Epidemic Preparedness Innovations. From the opening remarks, the tone was urgent. Prof. V.K. Paul, a senior figure in India's policy apparatus, laid out the central challenge: the region needed to stop waiting for crises to build research capacity. Instead, it needed systems ready to activate the moment an outbreak began.
To that end, WHO officials unveiled a draft framework built on six foundational pillars. The first two address the science itself—basic research and clinical-epidemiological work that generates understanding of new pathogens. The third pillar covers governance: the rules, approvals, and institutional structures that allow research to move at speed without cutting corners. The fourth tackles the practical side of vaccine development: manufacturing capacity and market dynamics. The fifth focuses on implementation research—how to actually get vaccines into arms once they exist. The sixth addresses the human dimension: behavioral science and communication strategies that build trust and uptake. Beneath these pillars sit five enabling systems: mechanisms for sharing data across borders, digital infrastructure, financing that can move quickly, partnerships that are already in place, and channels for exchanging knowledge.
The framework's ambition is clear: to create what officials called a "ready-to-activate research ecosystem" capable of generating evidence fast enough to guide policy decisions during an active outbreak or pandemic. But the architects of this plan understood something equally important: South-East Asia is not a monolith. Countries vary wildly in research capacity, regulatory sophistication, and manufacturing capability. Rather than demand uniform preparedness across all six pillars in all ten nations, the framework allows each country to build strength where it already has foundation, then tap into regional platforms for expertise and infrastructure it lacks. Smaller nations, in particular, saw value in this approach—they could access world-class technical support and facilities without building everything themselves.
The shift the participants endorsed was conceptual as much as practical. For decades, pandemic research has been reactive: a new virus emerges, the world scrambles to understand it, trials begin from scratch. The new model is proactive. It means pre-approved research protocols sitting ready on the shelf. It means clinical trial networks already established and trained. It means genomic surveillance systems already running, so variants are caught early. It means financing mechanisms that can unlock money in days, not months. It means regulatory bodies in different countries aligned enough that a trial approved in one place doesn't require complete re-review in another.
As the three days of discussion concluded, the message from the room was consistent: this framework only works if countries commit sustained investment, if partnerships hold firm, and if the region acts as one. The WHO and its partners framed this not as a burden but as an opportunity—a chance for South-East Asia to lead globally on pandemic preparedness, to meet ambitious targets like the 100-Day Mission (the goal of developing a vaccine within 100 days of a pathogen's identification), and to build research systems that serve not just crisis response but routine immunization work as well. The framework now moves toward implementation, with countries expected to assess their own capacities and begin aligning their research ecosystems to the model.
Citas Notables
The region needs to move toward a coordinated and pre-established research preparedness system to effectively respond to future pandemics— Prof. V.K. Paul, Member, NITI Aayog
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this meeting happened now, in 2026? Hasn't pandemic preparedness been a priority since COVID?
COVID exposed the gaps, yes, but the world has short memory. Without a framework in place and countries committed to it, preparedness atrophies. This meeting is about locking in the lessons before they fade.
The framework has six pillars. Why not just focus on vaccine development itself?
Because a vaccine is only useful if you understand the disease, can manufacture it at scale, get people to accept it, and have the regulatory pathways to move fast. You need the whole ecosystem, not just the lab.
The source mentions that not all countries need to be equally prepared. Doesn't that create weak links?
It's pragmatic. A small island nation can't build a vaccine manufacturing plant. But it can be part of a regional network, contribute what it's good at, and access what it needs. That's stronger than pretending everyone can do everything.
What does "pre-approved protocols" actually mean in practice?
Imagine the next outbreak starts tomorrow. Instead of researchers spending months designing a trial from scratch, they pull a protocol that's already been vetted by regulators, adapted it to the new pathogen, and start enrolling patients within weeks instead of months.
The 100-Day Mission—is that realistic?
It's ambitious, maybe impossible for some pathogens. But setting that target forces you to build systems that compress timelines everywhere. Even if you miss it, you're faster than you would have been.
Who actually has to do the work to make this real?
Each country has to assess where it stands, decide what to build and what to partner on. The WHO provides the blueprint, but implementation is on the governments and their research institutions.